Programme Structure and Funding
This is a full-time PhD programme with a duration of 4 years (8 semesters).
-
Study location: Freising
-
Application period: Enrolment possible throughout the year
-
Tuition: Tuition-free; from 2026, a semester fee of EUR 97 per semester is payable
-
Language of instruction: English
Entry Requirements
Academic background: 1) A master’s degree in biology, biochemistry, genetics, biophysics, bioinformatics or a related field. Applicants from top-ranked domestic institutions are preferred. 2) Completion of a master’s laboratory project in a relevant field (cell biology, genetics or biochemistry); relevant internship experience and publications are advantageous. Grade requirements: A master’s GPA of 3.0 or above, or 80 or above on the 100-point scale (Merit under the UK system); Language requirements:
- IELTS >= 7.0
- Or TOEFL total score of no less than 100
- Applicants who obtained a master’s degree in a country where instruction is in English may apply for a language exemption;
- German is advantageous References: None required, but references are an advantage
Application Period
Applications accepted throughout the year
Outstanding students may apply throughout the year
Tuition and Living Costs
Study and Living
- Housing: TUM students under the age of 30 may apply for university dormitories (places are limited); for off-campus renting, the university will provide you with specific information on how best to find accommodation
- Daily expenses: Living costs in Freising are estimated at around EUR 800 to 1,100 per month
Career Prospects
PhD graduates in cell biology and genetics from TUM are highly competitive in the job market thanks to their solid experimental skills, rigorous scientific thinking and ability to collaborate across disciplines. Their main career paths fall into the following broad categories:
Academia & Research
Postdoctoral training: Graduates commonly go on to postdoctoral research at German institutions such as the Max Planck Society (MPG), the Helmholtz Association (HZ) and Leibniz institutes, or at world-leading universities such as Harvard, MIT and Stanford in the US, or Oxford and Cambridge in the UK. Independent principal investigator (PI): After building up experience through the postdoctoral stage, the ultimate goal is to become an independent researcher, lead one’s own laboratory, secure third-party funding and train the next generation of scientists. Core facility specialist: With mastery of cutting-edge technologies (such as cryo-electron microscopy, bioimaging and bioinformatics), graduates become technical managers of core facilities at universities or research institutes.
Industry & the Pharmaceutical Sector
R&D: Joining well-known pharmaceutical companies such as Bayer, Roche, Pfizer, Novartis and BioNTech, working on core R&D activities such as novel drug target discovery, drug mechanism-of-action research and preclinical development. Medical affairs and scientific liaison: Acting as a bridge between science and clinical practice, responsible for interpreting and communicating the latest research findings and supporting product medical strategy. Biotechnology start-ups: Munich is one of Europe’s most active start-up hubs. Many graduates join or directly found biotechnology companies, turning academic ideas into practical applications or products.
Clinical & Medical Directions
Hospital research laboratories: Collaborating with university-affiliated hospitals (such as the Rechts der Isar Hospital) on translational medicine research, directly moving basic research findings towards clinical application. Genetic counselling/diagnostics: Joining medical diagnostics institutions, responsible for the analysis and interpretation of genetic disease data based on technologies such as NGS.
Consulting & Finance
Management consulting: Joining top consulting firms such as McKinsey, BCG and Bain, focusing on strategy consulting in the pharmaceutical and healthcare sectors. Venture capital (VC) and private equity (PE): Becoming investment analysts in the life sciences field, responsible for assessing the scientific feasibility and investment potential of biotechnology projects.
